Colorectal Cancer
Conditions
Keywords
Colorectal cancer, aspirin
Brief summary
The purpose of this research study is to understand the effects of oral aspirin taken daily with an arginine-restricted diet on certain colorectal cancer biomarkers in treated colorectal cancer patients. Patients with colorectal cancer are at high risk for recurrence and for development of secondary colorectal cancers in the future. Specific chemicals (polyamines, prostaglandins) in the body referred to as biomarkers can be measured to help understand a person's risk for developing colorectal cancer. Specific biomarkers associated with colorectal cancer have been identified in prior laboratory studies. By measuring these predefined biomarkers before and after the study intervention, we can assess how they are affected by the intervention, and gain knowledge about their usefulness in colorectal cancer patients on clinical trial. This study is a Phase IIa clinical biomarker study, using oral aspirin 325 mg taken daily with an arginine-restricted diet designed to reduce arginine intake by at least 30% during the 12-week study period. The biomarkers will be obtained from patient by performing endoscopy (a procedure used to look at the inside of the bowel, rectum and colon) and biopsy (taking samples of tissue), phlebotomy (drawing blood), and urine collection. Biopsies are done to evaluate changes in tissue content that may relate to early events in colon cancer formation. This was the procedure used to diagnose your condition initially. There will be 24 patients enrolled into this study performed through University of California Irvine Medical Center.
Interventions
DRUGAspirin
325 mg taken daily with an arginine-restricted diet
Sponsors
University of California, Irvine
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Subjects must be 18-80 years of age with a history of surgically removed colon or rectal cancer, and have received treatment for their disease using drugs (adjuvant chemotherapy) * Subjects must have colon or rectal cancer with stage I, II, or III disease * Subjects should not have further treatment with radiation therapy. Subjects having already received adjuvant (i.e., post-operative) radiation therapy to the colon or rectum will be excluded. However, subjects receiving radiation therapy prior to surgery for rectal cancer are eligible for enrollment. * Subject's tumor must have been completely removed within the past 12 months, with first surveillance colonoscopy anticipated 12 weeks after study treatment start date (i.e. one-year after surgical removal). * Subjects must be in good physical status * If subjects are premenopausal and perimenopausal women, they must be using adequate birth control methods. * Subjects must have no history of another invasive cancer within 5 years * Subjects must have no further chemotherapy anticipated. * Subjects don't have special dietary requirements or additives. Subjects must not be consuming a diet that would preclude taking the study medication. * Subjects must have no concomitant use of calcium supplements (\> 520mg/day). * Subjects must have no history of abnormal wound healing or repair, or conditions that predispose to the same. * Subjects don't have personal history of colon resection of or inflammatory bowel disease. * Subjects must give informed consent via consent form approved by the local Human Subjects Committee (Institutional Review Board). * If subjects are taking aspirin 81mg by mouth daily they will be eligible * Subjects must have no history of allergies or adverse reactions to aspirin. * Subjects don't have documented history of gastric/duodenal ulcer within the last 12 months.
Exclusion criteria
* Subjects already received radiation therapy to the colon or rectum. * Subjects adhering to vegetarian diets. * Subjects are pregnant or lactating women. * Subjects are breastfeeding * Subjects are already taking aspirin 325mg by mouth daily. * Subjects are taking combination medication with more than 81mg aspirin. * Subjects are currently being treated for gastric/duodenal ulcer or experiencing symptoms at study entry. * Subjects have a history of any medical condition that would place them at risk as a result of a blood donation, they will be excluded from the study. * Subjects are taking blood-thinning drugs as warfarin (Coumadin) * Subjects are allergic to fenoprofen, ibuprofen, indomethacin, ketoprofen, meclofenamate sodium, naproxen, sulindac, tolmetin, or an orange food coloring known as tartrazine. * Subjects have liver damage or severe kidney failure
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rectal Tissue Putrescine Reduction | 12 weeks | To demonstrate a \> 50% decrease in rectal tissue putrescine levels from baseline in study subjects, as a measure of polyamine reduction in the target tissue of colorectal cancer patients. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety/Toxicity | 12 weeks | To determine the number and proportion of patients with any grade 1 or greater side effect, using Common Terminology for Adverse Events v4.0 (CTCAE) |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| 325 mg Aspirin 325 mg aspirin po qd with arginine-restricted diet
Aspirin: 325 mg taken daily with an arginine-restricted diet | 20 |
| Total | 20 |
Baseline characteristics
| Characteristic | 325 mg Aspirin |
|---|---|
| Age, Continuous | 58 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 19 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 8 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 12 Participants |
| Region of Enrollment United States | 20 participants |
| Sex: Female, Male Female | 7 Participants |
| Sex: Female, Male Male | 13 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 20 |
| other Total, other adverse events | 6 / 20 |
| serious Total, serious adverse events | 0 / 20 |
Outcome results
Primary
Rectal Tissue Putrescine Reduction
To demonstrate a \> 50% decrease in rectal tissue putrescine levels from baseline in study subjects, as a measure of polyamine reduction in the target tissue of colorectal cancer patients.
Time frame: 12 weeks
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| 325 mg Aspirin | Rectal Tissue Putrescine Reduction | 17 Participants |
Secondary
Safety/Toxicity
To determine the number and proportion of patients with any grade 1 or greater side effect, using Common Terminology for Adverse Events v4.0 (CTCAE)
Time frame: 12 weeks
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| 325 mg Aspirin | Safety/Toxicity | 6 Participants |